Company Valuation: MINAPHARM Pharmaceuticals

Data adjusted to current consolidation scope
Fiscal Period: December 2020 2021 2022 2023 2024 2025
Market Cap 1 987 1,303 1,822 2,408 1,796 4,114
Change - 32.02% 39.82% 32.19% -25.41% 129.01%
Enterprise Value (EV) 1 922 1,570 2,562 4,297 4,395 5,224
Change - 70.23% 63.21% 67.74% 2.27% 18.88%
P/E 3.28x 2.91x 2.88x -43.5x 14x 584x
PBR 0.64x 0.69x 0.55x 0.7x 0.44x 0.66x
PEG - 0.1x 0.1x 0x -0x -6.2x
Capitalization / Revenue 0.42x 0.43x 0.5x 0.62x 0.32x 0.64x
EV / Revenue 0.39x 0.52x 0.71x 1.1x 0.78x 0.81x
EV / EBITDA 1.48x 1.89x 2.36x 8.02x 3.75x 3.87x
EV / EBIT 1.71x 2.1x 2.66x 11.5x 4.71x 5.13x
EV / FCF 3.33x -10.9x -4.11x -3.25x -10.3x -28.5x
FCF Yield 30.1% -9.18% -24.3% -30.7% -9.71% -3.51%
Dividend per Share 2 2.7 2.922 2.8 1.65 2.5 -
Rate of return 3.36% 2.76% 1.89% 0.76% 1.54% -
EPS 2 24.47 36.42 51.41 -5.006 11.58 0.5979
Distribution rate 11% 8.02% 5.45% -33% 21.6% -
Net sales 1 2,361 3,005 3,621 3,892 5,665 6,438
EBITDA 1 621.7 828.5 1,086 536 1,172 1,348
EBIT 1 538.8 746.5 964.7 374.7 933.8 1,019
Net income 1 300.8 466.4 612.7 -31.99 157.1 40.22
Net Debt 1 -65.01 266.5 739.6 1,889 2,598 1,110
Reference price 2 80.29 106.00 148.21 217.68 162.36 349.20
Nbr of stocks (in thousands) 12,293 12,293 12,293 11,064 11,064 11,781
Announcement Date 31/3/21 31/3/22 30/3/23 7/4/24 12/6/25 10/6/26
1EGP in Million2EGP
Estimates


P/E (Y) EV / Sales (Y) EV / EBITDA (Y) Dividend Yield (Y) Capi.($)
- - - - 169M
39.41x13.36x28.32x0.51% 1,200B
36.94x6.65x18.71x1.97% 651B
36.49x8.39x17.36x2.41% 506B
21.41x5.17x12.95x2.53% 377B
94.91x5.47x23.3x2.54% 330B
22.98x5.56x13.52x2.87% 288B
23.04x4.63x13.15x1.9% 272B
22.71x6.96x12.8x2.32% 236B
-39.14x7.25x45.66x1.98% 206B
Average 28.75x 7.05x 20.64x 2.11% 407B
Weighted average by Cap. 34.26x 8.45x 21.50x 1.77%

Y-o-Y evolution of P/E

Valuation ratios - P/E - MINAPHARM Pharmaceuticals

Historical PBR trend

Valuation ratios - PBR - MINAPHARM Pharmaceuticals

Evolution Enterprise Value / Sales

Valuation ratios - VE_REV - MINAPHARM Pharmaceuticals

Change in Enterprise Value/EBITDA

Valuation ratios - VE_EBITDA - MINAPHARM Pharmaceuticals

  1. Stock Market
  2. Stocks
  3. MIPH Stock
  4. Valuation MINAPHARM Pharmaceuticals